Monte Rosa Therapeutics files IND application for molecular glue degrader MRT-6160

June 27, 2024

Monte Rosa Therapeutics Inc. has submitted an IND application to the FDA for MRT-6160, a highly selective and orally bioavailable molecular glue degrader directed against VAV1 in development for systemic and neurological autoimmune diseases.

BioWorld Science Regulatory Dermatologic Gastrointestinal Musculoskeletal Neurology/psychiatric Degradation inducer IND

Today's news in brief

BioWorld

BioWorld briefs for March 26, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 26, 2025

Lost in trans-lation? Trump’s mouse charge doesn’t click

BioWorld

U.S. President Donald Trump touched off a not-uncommon flurry of puzzlement and outrage when, during his speech to Congress on March 4, he referred to an example...

Gene therapy efforts active, despite low Bluebird, 2seventy bids

BioWorld

Bristol Myers Squibb Co.’s decision this week to snag Bluebird Bio Inc. spinout 2seventy Bio Inc. for $102 million net – just weeks after investors bid $30...

CMV history cited in DMD liver death on Sarepta’s Elevidys

BioWorld

Wall Street was weighing the gravity of the death from acute liver failure of a patient who was treated for Duchenne muscular dystrophy (DMD) with Sarepta...